查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953548

糖尿病藥物市場 - 全球產業規模、佔有率、趨勢、機會及預測（按藥物類別、糖尿病類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年）

Diabetes Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Diabetes Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球糖尿病治療市場預計將從 2025 年的 912.3 億美元成長到 2031 年的 1,399.3 億美元，年複合成長率為 7.39%。

這些藥物，包括胰島素和口服降血糖藥，對於調節第1型和第2型糖尿病患者的血糖值至關重要。推動這一市場成長的主要因素是全球慢性代謝性疾病發生率的上升，而這又與人口老化、都市化和肥胖率上升密切相關。越來越多的患者需要持續的藥物治療來控制病情並預防嚴重的生理併發症。根據國際糖尿病聯盟（IDF）預測，到2024年，全球將有約5.89億成年人罹患糖尿病。

市場概覽
預測期 2027-2031
市場規模：2025年 912.3億美元
市場規模：2031年 1399.3億美元
複合年成長率：2026-2031年 7.39%
成長最快的細分市場 GLP-1受體促效劑
最大的市場 北美洲

儘管市場需求強勁，但先進治療方法的高昂費用是阻礙市場發展的主要障礙，這限制了開發中國家的用藥途徑。新型生物製藥及其長期治療的高昂成本往往難以在價格敏感族群中廣泛應用。因此，低收入地區缺乏可負擔性以及報銷體係不完善仍然是全球製藥業在該領域實現最佳成長的主要障礙。

市場促進因素

全球糖尿病盛行率的快速成長，尤其是肥胖率上升和久坐不動的生活方式，是推動全球糖尿病治療市場發展的主要動力。患者群體的快速擴大，使得已開發國家和開發中國家都迫切需要有效的藥物療法。隨著代謝性疾病的日益普遍，醫療衛生系統被迫優先考慮可及的治療方法，以減少長期併發症，從而確保製藥公司穩定的收入來源。為了說明這項負擔的嚴重性，非傳染性疾病風險因子合作組織和世界衛生組織（世衛組織）在2024年11月估計，到2022年，全球將有8.28億成年人患有糖尿病。

同時，新型治療藥物和生物製藥，特別是Glucagon-Like Peptide-1(GLP-1) 受體促效劑的引入，正在從根本上改變競爭格局。這些先進療法憑藉其強效血糖控制和顯著體重管理的雙重優勢，推動了市場擴張，並改變了處方趨勢，使其不再依賴傳統的口服降血糖藥物。這種臨床療效正轉化為產業主要創新者的顯著財務成長。例如，2024年11月，諾和諾德公司報告稱，其用於治療第2型糖尿病的GLP-1類藥物在當年前九個月的銷售額成長了26%。 2024年10月，禮來公司宣布，其糖尿病治療藥物Munjaro僅在第三季就實現了31.1億美元的全球收入。

市場挑戰

先進治療方法的高成本對全球糖尿病藥物市場構成重大障礙，尤其是在價格敏感且疾病負擔成長最快的地區。儘管患者人數不斷增加，但引進新型高效藥物的經濟能力往往落後。在許多開發中國家，有限的健保報銷體系迫使病患自費，這種經濟差距限制了高階生物製藥在富裕國家的市場滲透，導致全球很大一部分人口依賴利潤微薄的學名藥。

這種經濟差距直接阻礙了製藥業從不斷成長的患者群體中獲利的能力。管理這種疾病的巨額資金表明，它給全球醫療保健系統帶來了沉重的負擔。根據國際糖尿病聯盟（IDF）估計，到2024年，全球與糖尿病相關的醫療保健費用將達到1兆美元。然而，由於大部分支出集中在高所得國家，製藥公司面臨結構性成長限制。新興市場仍未能充分利用患者群體，因為這些患者群體獲得最盈利治療方法的機會有限。

市場趨勢

超長效、每週一次的基礎胰島素的問世，標誌著在減輕每日注射負擔方面取得了重大突破，而每日注射往往會降低患者的治療依從性。這項創新採用了一種新的配方，延長了基礎胰島素的半衰期，簡化了第二型糖尿病患者的治療方案。研發人員正在推動這些候選藥物的臨床試驗，以證明其療效不劣於標準治療方案。根據禮來公司2024年9月發布的關於QWINT III期臨床試驗的新聞稿，每週一次的胰島素Efitra alfa在52週時使糖化血紅蛋白（A1C）水平降低了1.31%，其療效與每日注射甘精胰島素相當。

同時，經濟實惠的胰島素生物相似藥正日益滲透市場，為生物製藥提供價格較親民的替代方案，從而改變整個產業格局。專利到期以及醫療系統在確保患者用藥可及性的同時降低採購成本的需求，推動了這一趨勢的發展。這些藥物的快速商業性化應用表明，全球支付方對其接受度正在不斷提高。根據山德士2024年11月發布的報告，其生物相似藥部門今年前九個月的銷售額達到21億美元，以外匯匯率計算增加了32%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球糖尿病藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類別（胰島素、DPP-4抑制劑、GLP-1受體促效劑、SGLT2抑制劑、其他）
    • 依糖尿病類型（第一型糖尿病、2 型糖尿病、妊娠糖尿病）
    • 給藥途徑（口服、皮下注射、靜脈注射）
    • 按分銷管道（網上藥局、醫院藥局、零售藥局、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美糖尿病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲糖尿病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區糖尿病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲糖尿病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲糖尿病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球糖尿病藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novo Nordisk A/S
  • Sanofi
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27560

The Global Diabetes Drugs Market is projected to expand from a valuation of USD 91.23 Billion in 2025 to USD 139.93 Billion by 2031, reflecting a CAGR of 7.39%. These pharmaceutical agents, including insulin and oral hypoglycemics, are essential for regulating blood glucose levels in patients diagnosed with Type 1 and Type 2 diabetes. The central catalyst for this market growth is the rising global incidence of chronic metabolic disorders, driven by aging demographics, urbanization, and increasing obesity rates. This expanding patient population necessitates continuous pharmacotherapy to manage the condition and prevent severe physiological complications; according to the International Diabetes Federation, approximately 589 million adults were living with diabetes worldwide in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 91.23 Billion
Market Size 2031USD 139.93 Billion
CAGR 2026-20317.39%
Fastest Growing SegmentGLP-1 Receptor Agonists
Largest MarketNorth America

Despite this strong demand, a major obstacle potentially hindering market progress is the prohibitive cost of advanced treatment regimens, which limits accessibility in developing economies. The significant financial expense associated with newer biologics and long-term management often restricts widespread adoption among price-sensitive populations. Consequently, the lack of affordability and inadequate reimbursement structures in low-income regions remain substantial barriers to the optimal growth of the global pharmaceutical sector in this domain.

Market Driver

The surging global prevalence of diabetes, significantly intensified by rising obesity rates and sedentary lifestyles, serves as the primary force propelling the Global Diabetes Drugs Market. This rapidly growing patient base creates an urgent and sustained need for effective pharmacotherapy across both developed and developing nations. As metabolic disorders become more pervasive, healthcare systems are compelled to prioritize accessible treatments to mitigate long-term complications, thereby securing a consistent revenue stream for pharmaceutical manufacturers; highlighting the scale of this burden, the NCD Risk Factor Collaboration and the World Health Organization estimated in November 2024 that 828 million adults globally were living with diabetes in 2022.

Concurrently, the adoption of novel therapeutic classes and biologics, particularly Glucagon-Like Peptide-1 (GLP-1) receptor agonists, is fundamentally reshaping the competitive landscape. These advanced therapies are driving market expansion by offering the dual benefits of robust glycemic control and significant weight management, shifting prescription trends away from traditional oral hypoglycemics. This clinical efficacy has translated into substantial financial growth for key industry innovators; for instance, Novo Nordisk reported in November 2024 that sales of GLP-1-based products for type 2 diabetes increased by 26% during the first nine months of the year, while Eli Lilly and Company announced in October 2024 that worldwide revenue for the diabetes medication Mounjaro reached $3.11 billion in the third quarter alone.

Market Challenge

The high cost of advanced therapeutic regimens constitutes a significant barrier to the Global Diabetes Drugs Market, particularly in price-sensitive regions where the disease burden is growing most rapidly. Although the patient population is expanding, the economic capacity to adopt newer, high-efficacy pharmaceutical agents often lags behind. In many developing economies, limited reimbursement frameworks force patients to rely on out-of-pocket payments, a financial disparity that restricts the market penetration of premium biologics to wealthy nations while leaving a vast segment of the global population dependent on older, lower-margin generic alternatives.

This affordability gap directly impedes the industry's ability to monetize the widening patient base. The financial magnitude of managing this condition illustrates the strain on global health systems; according to the International Diabetes Federation, diabetes was responsible for an estimated USD 1 trillion in global health expenditure in 2024. However, because a significant portion of this spending is concentrated in high-income nations, pharmaceutical companies face a structural limit on growth, as they remain unable to fully capitalize on the volume of patients in emerging markets who are financially excluded from accessing the most profitable treatment options.

Market Trends

The introduction of Ultra-Long-Acting Once-Weekly Basal Insulins represents a critical shift aimed at mitigating the burden of daily injections, which often compromises treatment adherence. This innovation utilizes novel formulations to extend basal insulin half-life, simplifying treatment schedules for Type 2 diabetes patients. Developers are advancing these candidates through trials to prove non-inferiority against daily standards; according to Eli Lilly and Company's September 2024 press release regarding the Phase 3 QWINT clinical trials, the once-weekly insulin efsitora alfa demonstrated efficacy by reducing A1C levels by 1.31% at week 52, comparable to daily insulin glargine.

Simultaneously, the increasing market penetration of Cost-Effective Insulin Biosimilars is reshaping the sector by offering affordable alternatives to biologic originators. This trend is accelerated by patent expirations and the need for healthcare systems to lower procurement costs while maintaining patient access. The rapid commercial uptake of these agents highlights their growing acceptance among global payers; according to Sandoz's November 2024 report, global net sales for the company's biosimilars division reached USD 2.1 billion for the first nine months of the year, marking a 32% increase in constant currencies.

Key Market Players

  • Novo Nordisk A/S
  • Sanofi
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.

Report Scope

In this report, the Global Diabetes Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetes Drugs Market, By Drug Class

  • Insulin
  • DPP-4 Inhibitors
  • GLP-1 Receptor Agonists
  • SGLT2 Inhibitors
  • Others

Diabetes Drugs Market, By Diabetes Type

  • Type 1
  • Type 2
  • Gestational

Diabetes Drugs Market, By Route of Administration

  • Oral
  • Subcutaneous
  • Intravenous

Diabetes Drugs Market, By Distribution Channel

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Diabetes Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetes Drugs Market.

Available Customizations:

Global Diabetes Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diabetes Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others)
    • 5.2.2. By Diabetes Type (Type 1, Type 2, Gestational)
    • 5.2.3. By Route of Administration (Oral, Subcutaneous, Intravenous)
    • 5.2.4. By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Diabetes Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Diabetes Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Diabetes Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Diabetes Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Diabetes Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Diabetes Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Diabetes Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Diabetes Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Distribution Channel

7. Europe Diabetes Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Diabetes Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Diabetes Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Diabetes Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. France Diabetes Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Diabetes Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Diabetes Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Diabetes Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Diabetes Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Diabetes Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Diabetes Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Diabetes Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Diabetes Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Diabetes Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Diabetes Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Diabetes Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Diabetes Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Diabetes Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Diabetes Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Diabetes Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Diabetes Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Diabetes Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Diabetes Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Diabetes Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Diabetes Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Diabetes Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Diabetes Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Diabetes Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. UAE Diabetes Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Diabetes Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. South Africa Diabetes Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Diabetes Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel

10. South America Diabetes Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Diabetes Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Diabetes Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Diabetes Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Colombia Diabetes Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Diabetes Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Argentina Diabetes Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Diabetes Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Diabetes Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novo Nordisk A/S
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sanofi
  • 15.3. Merck & Co., Inc.
  • 15.4. Eli Lilly and Company
  • 15.5. AstraZeneca PLC
  • 15.6. Takeda Pharmaceutical Company Limited
  • 15.7. Boehringer Ingelheim International GmbH
  • 15.8. Novartis AG
  • 15.9. Bayer AG
  • 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer